(Q38599586)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26438084%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

title

Analogue peptides for the immunotherapy of human acute myeloid leukemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26438084%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26438084%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Barbara Guinn

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26438084%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

author name string

Susanne Hofmann

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26438084%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Aleksandrs Malinovskis

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26438084%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Nicola R Hardwick

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26438084%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

publication date

5 October 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26438084%20AND%20SRC:MED&resulttype=core&format=json

Cancer Immunology, Immunotherapy

26 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26438084%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

volume

64

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26438084%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26438084%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

page(s)

1357-1367

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26438084%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00262-015-1762-9

26 February 2020

exact match

0 references

cites work

Immunotherapy of myeloid leukaemia.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

An immune edited tumour versus a tumour edited immune system: Prospects for immune therapy of acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Development of a whole cell vaccine for acute myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Human neoplasms elicit multiple specific immune responses in the autologous host

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Humoral detection of leukaemia-associated antigens in presentation acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

"Wilms Tumor Protein 1" (WT1) peptide vaccination-induced complete remission in a patient with acute myeloid leukemia is accompanied by the emergence of a predominant T-cell clone both in blood and bone marrow.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Combined triggering of dendritic cell receptors results in synergistic activation and potent cytotoxic immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Vaccination regimens incorporating CpG-containing oligodeoxynucleotides and IL-2 generate antigen-specific antitumor immunity from T-cell populations undergoing homeostatic peripheral expansion after BMT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

More than one reason to rethink the use of peptides in vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Enhanced cytotoxicity and decreased CD8 dependence of human cancer-specific cytotoxic T lymphocytes after vaccination with low peptide dose.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

21 January 2018

Acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2'-deoxycytidine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Regulation of HLA class I and II expression by interferons and influenza A virus in human peripheral blood mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Cryptic T-cell epitopes and their role in the pathogenesis of autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Identification of a new HLA-A*0201-restricted cryptic epitope from CYP1B1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Structural and kinetic basis for heightened immunogenicity of T cell vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Peptide-MHC class I stability is a better predictor than peptide affinity of CTL immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Analogues of CTL epitopes with improved MHC class-I binding capacity elicit anti-melanoma CTL recognizing the wild-type epitope

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Cytotoxic T cells generated against heteroclitic peptides kill primary tumor cells independent of the binding affinity of the native tumor antigen peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Rational design of peptide-based tumor vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Immunotherapy with gene-modified T cells: limiting side effects provides new challenges.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Heteroclitic CD33 peptide with enhanced anti-acute myeloid leukemic immunogenicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Identification of novel CD33 antigen-specific peptides for the generation of cytotoxic T lymphocytes against acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

CD8+ T-cell responses to tumor-associated antigens correlate with superior relapse-free survival after allo-SCT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-kappaB in AML carrying NPM1 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Donor lymphocyte infusion induces polyspecific CD8(+) T-cell responses with concurrent molecular remission in acute myeloid leukemia with NPM1 mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

PML-RARA-targeted DNA vaccine induces protective immunity in a mouse model of leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Defining MHC class II T helper epitopes for WT1 tumor antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Genetic basis for clinical response to CTLA-4 blockade in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Cancer stem cells: perspectives for therapeutic targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Somatically mutated tumor antigens in the quest for a more efficacious patient-oriented immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

The simultaneous ex vivo detection of low-frequency antigen-specific CD4+ and CD8+ T-cell responses using overlapping peptide pools.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Peptide vaccination after T-cell transfer causes massive clonal expansion, tumor eradication, and manageable cytokine storm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1762-9

10.1007/S00262-015-1762-9

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26438084%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

26 February 2020

1053032300

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26438084%20AND%20SRC:MED&resulttype=core&format=json